Global IT and Finance Leaders Survey Finds Biggest Blocker to Innovation is Overspending on “Keeping the Lights On”
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today revealed the results of a recently commissioned global survey to better understand the priorities and challenges IT and finance decision makers face when it comes to funding and investing in innovation. The survey, conducted by Vanson Bourne, a technology market research firm, and analyzed by llan Oshri, Professor of the Graduate School of Management, University of Auckland Business School, is based on responses from 900 CIOs, IT leaders and financial decision makers from a broad range of industries, located in North America, South America, Europe, Middle East and Africa, and Asia-Pacific.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180613005299/en/
Global IT and Finance Leaders Survey Finds Biggest Blocker to Innovation is Overspending on “Keeping the Lights On” (Photo: Business Wire)
A key finding of this research is that despite recognizing the importance of innovation and business transformation, IT and finance leaders face major roadblocks including “spending too much keeping the lights on” (77%), “lack of board support for significant investment in innovation” (76%), and being “locked in to vendor contracts that restrict innovation” (74%).
Balancing Innovation Spend with Maintaining Business Operations
While most organizations claim to have the drive and ambition to be an innovator, 71% of the global survey respondents indicated that their firms struggle to find budget for these initiatives. With shrinking to flat IT budgets, IT and finance decision makers are challenged to pursue and invest in growth strategies for their business, while balancing this directive with the significant budget required to maintain and run their current operations.
Getting the Board On Board
Also topping the list of obstacles faced by IT and finance leaders when seeking budget for transformational initiatives, 76% of respondents cited “lack of board support for significant investment in innovation.” While the survey confirms there is innovation leadership at the board level, half of the respondents also note that they failed to convince the board that investing in innovation was critical for the business.
There was also agreement among respondents that the board refrains from complex, transformation projects that integrate the entire IT infrastructure (64%), the board is more focused on cost-cutting than innovation (63%), and the board is not confident that the firm has the skills to meet innovation objectives (57%).
These board-level attitudes to investment in transformational projects create a major challenge for those forward-looking CIOs and IT and finance leaders focused on supporting the organization's growth and competitive edge.
So how do IT and finance leaders shift this board mindset to receive approval to move forward with their much needed business transformation initiatives?
llan Oshri, Professor of the Graduate School of Management, University of Auckland Business School, and author of the report, “IT Leaders Frustrated with Barriers to Innovation and Falling Behind,” based on the Vanson Bourne research data, said that investing in innovation requires an organizational culture that encourages taking risks and accepting failure in order to learn.
“Most companies are more comfortable producing predictable and reliable outcomes, and are less inclined to challenge accepted conventions within the business. This risk mitigation approach is embedded into their DNA,” said Oshri. “However, organizations that excel in innovation embrace a dual mentality that balances investments in uncertain, but transformative, innovation projects with a focus on operational excellence. This balance is extremely challenging, but essential, in order to succeed today and in the future.”
The Benefits and Demonstrable ROI from Investment in Innovation
Demonstrating “hard” ROI is essential to gaining the board’s support for innovation spend. Clearly evident in the survey data was the fact that a return on investment is the secret sauce to more spending on innovation. Over a third of respondents reported their organization has already generated increased revenues (37%) or reduced operating costs (35%) as a result of their investment in innovation. Those respondents also respectively report a 14% average increase in annual revenue and a 12% decrease on average in operating costs. Additionally, 83% of the respondents acknowledged a clear link between IT innovation and their competitive industry position. The question then remains, with these statistics, why did half of the respondents cite that they have not been able to convince the board of the critical need to invest in innovation initiatives?
The survey revealed that those respondents who stated they have already experienced increased revenues as a result of their organization’s investment in innovation are less worried about their innovation budget, and are more likely to be able to convince the board to further invest in innovation. The same group also reported that they have already experienced improved productivity (62%), increased customer satisfaction (60%), and greater competitiveness (53%) – all as a result of their innovation spend.
According to Dave Jackson, CIO of Welch’s, a $700 million processing and marketing subsidiary of the National Grape Cooperative, as the company recognized changes in consumer buying habits, their strategy shifted to IT cost containment to reinvest savings and resources in new marketing initiatives.
“Welch’s required a strategy that would support increased business functionality and innovation while reducing costs,” said Jackson. “We knew we needed to invest in the future and maximize our IT budget simultaneously, so we shifted budget by moving to a third-party support model and immediately saved approximately 70% of our annual maintenance and other associated costs. That has helped us further our IT strategy by innovating around the edges of our core ERP with cloud technologies.”
Mega Vendor Strategies Hinder Innovation
Many survey respondents cited concern about the over-reliance on their organization’s enterprise application software vendors. In addition to the 74% who stated that being “locked in to vendor contracts that restrict innovation” was an obstacle to innovation, 54% agreed that they are being pressured to adopt their organization’s vendor’s cloud strategy. Many respondents are also seeking clarity on the vendor’s cloud application roadmap.
Lack of innovation from the traditional software vendors, coupled with the pressure to respond to evolving business needs faster, is driving IT and finance leaders to look at new strategies to reallocate capital and resources to innovation and growth. This reality requires a significant rethinking of cost components and budget trade-offs, and exploring innovative options across the entire IT landscape including third-party support for their enterprise applications.
“This survey highlights that while CIOs and IT and finance decision makers understand the strategic value of investing in innovation and want to invest more to reap the many benefits cited, they continue to struggle to secure the funds needed to make these investments that are so critical to their business growth,” said Hari Candadai, group vice president, Global Product Marketing and Strategy. “We understand this push-pull dynamic, and are focused on helping our more than 1,580 clients today maximize the value of their enterprise software and liberate the considerable funds that are ‘hidden’ in their IT software support. This enables our clients to redirect these savings into business transformation projects which will not only help them maintain a competitive edge, but will also earn them additional merit with their CEO and board of directors for future innovation investment requests.”
About Vanson Bourne
Vanson Bourne is an independent specialist in market research for the technology sector. Its reputation for robust and credible research-based analysis is founded upon rigorous research principles and an ability to seek the opinions of senior decision makers across technical and business functions, in all business sectors and all major markets. For more information, visit www.vansonbourne.com.
About Rimini Street, Inc.
Rimini Street, Inc. (Nasdaq: RMNI) is a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products. The company has redefined enterprise software support services since 2005 with an innovative, award-winning program that enables licensees of IBM, Microsoft, Oracle, Salesforce, SAP and other enterprise software vendors to save up to 90 percent on total support costs. Clients can remain on their current software release without any required upgrades for a minimum of 15 years. Over 1,580 global Fortune 500, midmarket, public sector and other organizations from a broad range of industries currently rely on Rimini Street as their trusted, third-party support provider. To learn more, please visit https://www.riministreet.com/, follow @riministreet on Twitter and find Rimini Street on Facebook and LinkedIn. (C-RMNI)
Certain statements included in this communication are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “may,” “should,” “would,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “seem,” “seek,” “continue,” “future,” “will,” “expect,” “outlook” or other similar words, phrases or expressions. These forward-looking statements include, but are not limited to, statements regarding our second quarter and annual 2018 revenue guidance, industry, future events, future opportunities and growth initiatives, hiring plans, estimates of Rimini Street’s total addressable market, and projections of customer savings. These statements are based on various assumptions and on the current expectations of management and are not predictions of actual performance, nor are these statements of historical facts. These statements are subject to a number of risks and uncertainties regarding Rimini Street’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, changes in the business environment in which Rimini Street operates, including inflation and interest rates, and general financial, economic, regulatory and political conditions affecting the industry in which Rimini Street operates; adverse litigation developments or government inquiry; the final amount and timing of any refunds from Oracle related to our litigation; our ability to refinance existing debt on favorable terms; changes in taxes, laws and regulations; competitive product and pricing activity; difficulties of managing growth profitably; the success of our recently introduced products and services, including Rimini Street Mobility, Rimini Street Analytics, Rimini Street Advanced Database Security, and services for Salesforce Sales Cloud and Service Cloud products; the loss of one or more members of Rimini Street’s management team; uncertainty as to the long-term value of RMNI common stock; and those discussed under the heading “Risk Factors” in Rimini Street’s Annual Report on Form 10-K filed on March 15, 2018, as updated from time to time by Rimini Street’s Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings by Rimini Street with the Securities and Exchange Commission. There may be additional risks that Rimini Street presently knows or that Rimini Street currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements provide Rimini Street’s expectations, plans or forecasts of future events and views as of the date of this communication. Rimini Street anticipates that subsequent events and developments will cause Rimini Street’s assessments to change. However, while Rimini Street may elect to update these forward-looking statements at some point in the future, Rimini Street specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Rimini Street’s assessments as of any date subsequent to the date of this communication.
© 2018 Rimini Street, Inc. All rights reserved. “Rimini Street” is a registered trademark of Rimini Street, Inc. in the United States and other countries, and Rimini Street, the Rimini Street logo, and combinations thereof, and other marks marked by TM are trademarks of Rimini Street, Inc. All other trademarks remain the property of their respective owners, and unless otherwise specified, Rimini Street claims no affiliation, endorsement, or association with any such trademark holder or other companies referenced herein.
Rimini Street, Inc.
Michelle McGlocklin, +1 925-523-8414
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 11:00 | Pressemelding
Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines
Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 08:10 | Pressemelding
Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 15:13 | Pressemelding
Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,
Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 14:00 | Pressemelding
Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 13:41 | Pressemelding
Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 12:00 | Pressemelding
Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i